- Home
- GXAI vs ALLR Comparison
GXAI vs ALLR Comparison
Compare GXAI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- ALLR
- Stock Information
- Founded
- GXAI 2021
- ALLR 2004
- Country
- GXAI United States
- ALLR United States
- Employees
- GXAI N/A
- ALLR N/A
- Industry
- GXAI
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- ALLR Health Care
- Exchange
- GXAI Nasdaq
- ALLR Nasdaq
- Market Cap
- GXAI 19.7M
- ALLR 15.8M
- IPO Year
- GXAI 2023
- ALLR N/A
- Fundamental
- Price
- GXAI $2.08
- ALLR $0.94
- Analyst Decision
- GXAI
- ALLR Strong Buy
- Analyst Count
- GXAI 0
- ALLR 1
- Target Price
- GXAI N/A
- ALLR $9.00
- AVG Volume (30 Days)
- GXAI 14.7M
- ALLR 376.0K
- Earning Date
- GXAI 08-13-2025
- ALLR 08-15-2025
- Dividend Yield
- GXAI N/A
- ALLR N/A
- EPS Growth
- GXAI N/A
- ALLR N/A
- EPS
- GXAI N/A
- ALLR N/A
- Revenue
- GXAI $198,711.00
- ALLR N/A
- Revenue This Year
- GXAI N/A
- ALLR N/A
- Revenue Next Year
- GXAI N/A
- ALLR N/A
- P/E Ratio
- GXAI N/A
- ALLR N/A
- Revenue Growth
- GXAI 72158.55
- ALLR N/A
- 52 Week Low
- GXAI $1.00
- ALLR $0.61
- 52 Week High
- GXAI $7.50
- ALLR $6.00
- Technical
- Relative Strength Index (RSI)
- GXAI 62.20
- ALLR 47.03
- Support Level
- GXAI $1.03
- ALLR $0.85
- Resistance Level
- GXAI $2.96
- ALLR $1.01
- Average True Range (ATR)
- GXAI 0.24
- ALLR 0.05
- MACD
- GXAI 0.15
- ALLR -0.01
- Stochastic Oscillator
- GXAI 54.64
- ALLR 47.55
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.